Bharwani A, Szamosi JC, Taylor VH, Lee Y, Bala A, Mansur R, et al
Medically reviewed by Mohammed Lakhi Superintendent Pharmacist Retatrutide UK 2026: Availability, Trial Results & Legal Status Updated 31 July 2026 Clinically reviewed The short answer: Retatrutide is not licensed in the UK
The UKPDS OM2 is a microsimulation model, which considers the complications of myocardial infarction, congestive heart failure, stroke, ischemic heart disease, amputation, end-stage renal disease (ESRD) or renal failure, blindness, and ulcer [19, 21, 29]
This authorized generic contains the same active ingredient and dosage strength as Januvia but is sold under a non-branded label, which could help lower costs once distribution expands